1,019 reports of this reaction
3.4% of all LIFITEGRAST reports
#8 most reported adverse reaction
INSTILLATION SITE REACTION is the #8 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 1,019 FDA adverse event reports linking LIFITEGRAST to INSTILLATION SITE REACTION. This represents approximately 3.4% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience instillation site reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSTILLATION SITE REACTION is moderately reported among LIFITEGRAST users, representing a notable but not dominant share of adverse events.
In addition to instillation site reaction, the following adverse reactions have been reported for LIFITEGRAST:
INSTILLATION SITE REACTION has been reported as an adverse event in 1,019 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSTILLATION SITE REACTION accounts for approximately 3.4% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience instillation site reaction while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.